

AMENDMENTS TO THE CLAIMS

Claims 1-25 canceled.

26. (Currently amended) A propellant free buccal spray composition for administration of pharmacological active compounds comprising:

an active compound in an amount of between 0.001 and 60 percent by weight of the total composition comprising a biologically active peptide, central nervous system active amine, sulfonyl urea, antibiotics, antifungals, sleep inducer, antiasthmatics, antiemetic, antiviral, histamine H-2 receptor antagonist, barbiturate, prostaglandin or bronchial dilator selected from terbutaline and theophyline; and

a polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is capable of providing ~~adapted for~~ transmucosal absorption of the active compound through the oral mucosa of when ~~administered to~~ a mammal to ~~provide the active compound in the systemic circulatory~~ system of the mammal.

27. (Previously presented) The composition of claim 26, further comprising a flavoring agent in the amount of between 0.1 and 10 percent by weight of the total composition.

28. (Previously presented) The composition of claim 27, wherein the polar solvent is present in an amount between 27 and 98 percent by weight of the total composition, the active compound is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

29. (Previously presented) The composition of claim 28, wherein the polar solvent is present in an amount between 59 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

30. (Previously presented) The composition of claim 26, wherein the polar solvent comprises a polyethylene glycols having a molecular weight between 400 and 1000, C₂ to C₈ mono- and poly-alcohol or C₇ to C₁₈ alcohols of linear or branched configuration.

31. (Previously presented) The composition of claim 26, wherein the polar solvent comprises aqueous polyethylene glycol.

32. (Previously presented) The composition of claim 26, wherein the polar solvent comprises aqueous ethanol.

33. (Previously presented) The composition of claim 26, wherein the active compound comprises cyclosporine, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valerian, or a pharmaceutically acceptable salt thereof.

34. (Previously presented) The composition of claim 27, wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners or mixture thereof.

Claims 35 and 36 canceled.

37. (Currently amended) A method of administering a pharmacologically active compound to the systemic circulatory system of a mammal comprising spraying the oral mucosa of said mammal with the composition of claim 26.

38. (Previously presented) The method of claim 37, wherein the amount of the spray is predetermined.

Claims 39 – 52 canceled.

53. (Currently amended) A propellant free buccal spray composition for administration of a pharmacologically active compound comprising:

an active compound in an amount between 0.005 and 55 percent by weight of the total composition comprising a biologically active peptide, central nervous system active amine, sulfonyl urea, antibiotic, antifungal, sleep inducer, antiasthmatic, antiemetic, antiviral, histamine H-2 receptor antagonist, barbiturate, prostaglandin or bronchial dilator selected from terbutaline and theophyline; and

a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is capable of providing ~~adapted for~~ transmucosal absorption of the active compound through the oral mucosa ~~of when administered to~~ a mammal to ~~provide the active compound in the systemic circulatory system of the~~ mammal.

54. (Previously presented) The composition of claim 53, further comprising a flavoring agent in the amount between 0.1 and 10 percent by weight of the total composition.

55. (Previously presented) The composition of claim 54, wherein the non-polar solvent is present in an amount between 69 and 99 percent by weight of the total composition, the active compound is clozepine in an amount from between 0.5 and 30 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.

56. (Previously presented) The composition of claim 53, wherein the active compound comprises cyclosporine, clozapine, zidovudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valerian or a pharmaceutically acceptable salt thereof.

57. (Previously presented) The composition of claim 54, wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweetener or a mixture thereof.

58. (Previously presented) The composition of claim 53, wherein the solvent comprises a (C₂-C₂₄) fatty acid (C₂-C₆) esters, C₇-C₁₈ hydrocarbons of linear or branched configuration, C₂-C₆ alkanoyl ester or triglyceride of a C₂-C₆ carboxylic acid.

59. (Previously presented) The composition of claim 53, wherein the solvent comprises one or more fatty acid esters.

60. (Currently amended) A method of administering a pharmacologically active compound to the systemic circulatory system of a mammal comprising spraying the oral mucosa of said mammal with the composition of claim 53.

61. (Previously presented) The method of claim 60, wherein the amount of the spray is predetermined.

Claims 62 – 78 canceled.

79. (Currently amended) A buccal spray composition for administration of a pharmacologically active compound comprising:

an active compound in an amount between 0.005 and 55 percent by weight of the total composition comprising an antihistamine, alkaloid, hormone, benzodiazepine or narcotic analgesic;

a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is capable of providing adapted for transmucosal absorption of the active compound through the oral mucosa of when administered to a mammal to ~~provide the active compound in the systemic circulatory system of the mammal.~~